Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 3/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.43 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | ABL2 | P42684 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 2/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | VNN1 | O95497 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.39 |
| ▸ | HRH2 | P25021 | 2/20 | 0.39 |
| ▸ | HRH1 | P35367 | 2/20 | 0.39 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29650087 | 0.87 | HSD11B1 (0.53) | HSD11B1HRH3HSD11B2SIGMAR1EGLN2 | |
| SCHEMBL24493078 | 0.87 | HSD11B1 (0.53) | HSD11B1HRH3HSD11B2SIGMAR1EGLN2 | |
| SCHEMBL1575819 | 0.81 | GPR119 (0.57) | — | |
| SCHEMBL3425233 | 0.81 | HRH4 (0.42) | HRH3HRH4 | |
| SCHEMBL1626866 | 0.81 | HRH3 (0.51) | HRH3HRH2HRH1 | |
| SCHEMBL1625904 | 0.79 | KDM4E (0.41) | HRH3HRH4 | |
| SCHEMBL1626586 | 0.78 | HRH4 (0.43) | HRH3ABL1SRCABL2CTSS | |
| SCHEMBL3423454 | 0.78 | SRC (0.46) | ABL1SRCABL2CTSSCTSL | |
| SCHEMBL2192991 | 0.78 | HSD11B1 (0.54) | HSD11B1HSD11B2CTSSCTSLCTSK | |
| SCHEMBL13162856 | 0.78 | HRH3 (0.62) | HSD11B1HRH3HSD11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1737297-B1 | IMIDAZOLE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2012-12-19 | — | — | EP | disclosed |
| US-8039498-B2 | Imidazole compounds | JANSSEN PHARMACEUTICA NV (BE) | 2011-10-18 | — | — | US | disclosed |
| US-8017600-B2 | Imidazole compounds | JANSSEN PHARMACEUTICA NV (BE) | 2011-09-13 | — | — | US | disclosed |
| US-8017639-B2 | Imidazole compounds | JANSSEN PHARMACEUTICA NV (BE) | 2011-09-13 | — | — | US | disclosed |
| US-7956066-B2 | Imidazole compounds | JANSSEN PHARMACEUTICA NV (BE) | 2011-06-07 | — | — | US | disclosed |
| US-7956071-B2 | Imidazole compounds | JANSSEN PHARMACEUTICA NV (BE) | 2011-06-07 | — | — | US | disclosed |
| US-7956057-B2 | Imidazole compounds | JANSSEN PHARMACEUTICA NV (BE) | 2011-06-07 | — | — | US | disclosed |
| US-7951808-B2 | Imidazole compounds | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-31 | — | — | US | disclosed |
| US-7928131-B2 | Imidazole compounds | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-19 | — | — | US | disclosed |
| US-20100261899-A1 | IMIDAZOLE COMPOUNDS | BUZARD DANIEL J | 2010-10-14 | — | — | US | disclosed |
| US-20070173512-A1 | Imidazole compounds | JANSSEN PHARMACEUTICA, N.V. | 2007-07-26 | — | — | US | disclosed |
| US-20070173509-A1 | Imidazole compounds | JANSSEN PHARMACEUTICA, N.V. | 2007-07-26 | — | — | US | disclosed |
| US-20070173510-A1 | Imidazole compounds | JANSSEN PHARMACEUTICA, N.V. | 2007-07-26 | — | — | US | disclosed |
| US-20070149541-A1 | Imidazole compounds | JANSSEN PHARMACEUTICA, N.V. | 2007-06-28 | — | — | US | disclosed |
| EP-1737297-A2 | IMIDAZOLE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-01-03 | — | — | EP | disclosed |
| EP-1673348-A2 | BENZOIMIDAZOLE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-28 | — | — | EP | disclosed |
| US-20050261309-A1 | Imidazole compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-11-24 | — | — | US | disclosed |
| WO-2005092066-A2 | IMIDAZOLE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-10-06 | — | — | WO | disclosed |
| WO-2005044807-A2 | BENZOIMIDAZOLE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-05-19 | — | — | WO | disclosed |
| US-20050070550-A1 | Benzoimidazole compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070550-A1 | Benzoimidazole compounds | HRH4, HRH3, BRD4 | HSD11B1 3582/4885HRH3 2/4885HSD11B2 3665/4885 |
| US-20070173512-A1 | Imidazole compounds | HRH4, HRH3, HRH2 | HSD11B1 3442/4885HRH3 2/4885HSD11B2 3526/4885 |
| US-20070173509-A1 | Imidazole compounds | HRH4, HRH3, HRH2 | HSD11B1 3442/4885HRH3 2/4885HSD11B2 3526/4885 |
| US-20070149541-A1 | Imidazole compounds | HRH4, HRH3, HRH2 | HSD11B1 3442/4885HRH3 2/4885HSD11B2 3526/4885 |
| US-20070173510-A1 | Imidazole compounds | HRH4, HRH3, HRH2 | HSD11B1 3442/4885HRH3 2/4885HSD11B2 3526/4885 |
| US-20100261899-A1 | IMIDAZOLE COMPOUNDS | HRH4, HRH3, HRH2 | HSD11B1 3442/4885HRH3 2/4885HSD11B2 3526/4885 |
| US-20050261309-A1 | Imidazole compounds | HRH4, HRH3, HRH2 | HSD11B1 3442/4885HRH3 2/4885HSD11B2 3526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.